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	 A	 set	 of	 new	heteroquinone	 derivatives	bearing	 two	methoxycarbonylmethylthio	 groups	on
the	 benzoquinone	 ring	were	 synthesized	 and	 evaluated	 for	 CDC25B	phosphatase	 inhibitory
activity.	 All	 compounds	 inhibited	 the	 enzyme	 with	 IC50	 values	 in	 the	 micromolar	 range
regardless	of	the	size	and	heteroatoms	constituting	the	heterocycle	fused	to	the	quinone	ring.
Moreover,	 these	 quinonoid‐based	 compounds	 showed	 moderate	 antiproliferative	 activity
toward	two	cancer	cell	lines	(HeLa	and	MiaPaca‐2).	These	results	provide	additional	data	for
CDC25	inhibition	by	quinone‐type	derivatives	and	highlight	the	importance	of	substituents	on
the	quinonic	moiety.	
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1.	Introduction	
	
Cell	 signaling	 is	 regulated	 by	 covalent	 and	 reversible	
phosphorylation	 and	 dephosphorylation	 reactions,	 which	 are	
controlled	 by	 protein	 kinases	 and	 phosphatases.	 These	
signaling	 pathways	 are	 responsible	 for	 essential	 cell	 events	
such	as	growth,	division	or	death,	their	deregulation	leading	to	
the	apparition	of	pathologies	such	as	cancers.	Cell	components	
involved	 in	 cell	 cycle	 regulation	 and	 in	 the	 checkpoint	
machinery	 are	 considered	 as	promising	 targets	 in	 therapeutic	
and	especially	for	cancer	treatment.	Indeed,	inhibiting	cell	cycle	
progression	will	limit	cell	proliferation.	Among	possible	targets,	
cyclin‐dependent	 kinases	 (CDK)	 are	 currently	widely	 studied.	
Among	 CDK	 regulators,	 CDC25	 phosphatases	 have	 received	
increasing	 interest	 over	 the	past	 years.	 These	 enzymes	play	 a	
central	 role	 in	 cell	 cycle	 control	 in	 eukaryotes	 and	 in	 the	
checkpoint	 response	 to	 DNA	 damage	 [1‐3].	 Up‐regulation	 of	
CDC25	has	been	observed	 in	a	wide	variety	of	human	cancers	
[4,5]	 and	 the	 phosphatases	 are	 also	 involved	 in	 oncogenic	
transformation	[6].	
Consequently,	many	efforts	have	been	devoted	to	search	for	
CDC25	 inhibitors.	 The	 most	 potent	 are	 currently	 quinonoid‐
based	 structures,	 which	 have	 been	 extensively	 studied	 [7].	
Compounds	1	and	2	are	lead	compounds	with	IC50	values	of	5	
µM	and	125	nM,	 respectively	 (Figure	1)	 [8,9].	 They	 led	 to	 the	
preparation	 of	 a	 number	 of	 quinonic	 derivatives	 including	
heteroquinones	 [10]	 based	 on	 quinoline	 [11‐17],	 quinazoline	
[11],	phtalazine	[11],	quinoxaline	[16],	isoquinoline	[11,12,18],	
isoindole	 [19],	 pyrazole	 [19],	 isoxazole	 [19],	 isothiazole	 [19]	
and	 imidazole	 [14,19]	 scaffolds.	 Since	 sub‐micromolar	
activities	 and	 encouraging	 selectivities	 were	 observed	 with	
benzothiazolequinone,	 11,	 and	 benzoxazolequinone,	 12,	 [19]	
(Figure	1),	 these	 two	pharmacophores	were	 assembled	 into	 a	
bis‐quinone	moiety,	which	resulted	in	a	ca.	10‐fold	 increase	 in	
CDC25	phosphatase	inhibition.	In	addition,	this	compound	was	
demonstrated	 to	 inhibit	 the	 growth	 of	 human	 tumor	
xenografted	on	mice	[20].	
We	 previously	 reported	 the	 synthesis	 and	 the	 inhibitory	
activity	 of	 naphthoquinones	 and	 quinolinequinones,	 3‐6,	
bearing	 two	 identical	 alkylthio	 substituents	 on	 the	 quinone	
ring,	 these	 inhibitors	displaying	 IC50	values	 in	 the	micromolar	
range	 (Figure	 1)	 [17,21].	 Searching	 for	 a	 potent	
pharmacophore	 for	 CDC25	 inhibition,	 Lazo	 and	 colleagues	
identified	 the	 bis‐substituted	 naphthoquinone,	 2,	 (IC50	 =	 125	
nM)	 as	 well	 as	 quinoleine,	 isoquinoleine	 and	 imidazole	
derivatives,	7‐10,	as	micromolar	CDC25	inhibitors	[12].	
In	 order	 to	 evaluate	 the	 effects	 of	 five‐membered	
heterocycles	 fused	 to	 the	 quinone	 ring,	 Lavergne	 et	 al.	
synthesized	and	evaluated	a	set	of	heterocyclic	quinones	 [19].	
They	 observed	 that	 the	 nature	 of	 the	 heterocycle	 could	
modulate	 the	 activity	 of	 the	 quinonic	 derivatives	 mono‐
substituted	with	a	N,N‐dimethylethylenediamino	group	on	 the	
quinone	ring.	 In	 this	study,	 the	most	potent	 inhibitors	11	 and	
12	displayed	IC50	values	in	the	hundred	nanomolar	range	[19].	
In	 order	 to	 investigate	 the	 influence,	 on	 CDC25	
phosphatase	 activity,	 of	 five	 and	 six‐membered	 heterocycles	
fused	 to	 the	 1,4‐dione	 pharmacophore	 substituted	 with	 two	
alkylthio	groups,	we	designed,	synthesized	and	evaluated	a	set	
of	 nine	 heteroquinones	 bearing	 two	 methoxycarbonyl	
methylthio	substituents	on	the	quinone	core.	
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Figure	1. Inhibitors	of	CDC25	phosphatases.
	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
Melting	 points	 were	 determined	 on	 a	 Büchi	 B‐545	
apparatus	 and	are	uncorrected.	 1H	and	 13C	NMR	spectra	were	
measured	 on	 a	 Bruker	 Avance	 300	 or	 Avance	 III	 400	
spectrometers.	 IR	 spectra	 were	 recorded	 on	 a	 Nicolet	 Magna	
IR‐550	FT‐IR	spectrometer	using	KBr	pellets	or	an	ATR	module.	
Mass	 spectra	 were	 recorded	 on	 a	 Bruker	 Daltonics	 Esquire	
3000+	 or	 a	 Thermo	 Fischer	 Scientific	 Polaris	 Q	 ion‐trap	
spectrometer.	 High	 resolution	 mass	 spectra	 were	 obtained	
using	 a	 Thermoquest	 Orbitrap	 apparatus.	 Elemental	 analyses	
(Service	 d’Analyse	 du	 Département	 de	 Chimie	Moléculaire	 de	
Grenoble,	France)	were	performed	using	a	CHN	analyzer	built	
by	the	Service	Central	d’Analyses	du	CNRS	(Vernaison,	France).	
	
2.2.	Synthesis	
	
2.2.1.	Preparation	of	compounds	14‐17	and	21‐26	
	
2.2.1.1.	2,3‐Bis(1‐methoxycarbonylmethylthio)‐1,4‐
naphthoquinone	(14)	
	
To	 a	 mixture	 of	 2,3‐dichloro‐1,4‐naphthoquinone	 (50	mg,	
0.22	mmol)	and	pyridine	(50	µL,	0.62	mmol)	in	ethanol	(1	mL)	
at	 0	 °C	methyl	 thioglycolate	 (0.484	mmol,	 43	 µL)	was	 added.	
The	mixture	was	stirred	at	4	°C	for	68	hours	then	diluted	with	
ethanol.	 After	 filtration	 and	 evaporation	 of	 the	 volatiles,	 the	
residue	was	recrystallized	from	hot	acetone	to	give	pure	14	as	
dark	violet	needles.	Yield:	43%.	M.p.:	113	°C.	FT‐IR	(film):	2939,	
1738	(C=O),	1650	(C=O),	1583	(Aromatic	C=C),	1435,	1276,	
1164,	 1140	 cm‐1.	 1H	NMR	 (400	MHz,	 CDCl3,	,	 ppm):	 8.03	 (m,	
2H,	Ar‐H),	7.68	(m,	2H,	Ar‐H),	4.02	(s,	4H,	2CH2),	3.70	(s,	6H,	
2CH3).	13C	NMR	(100	MHz,	CDCl3,	,	ppm):	178.8	(2C=O),	169.3	
(2C=O),	 146.2	 (2C),	 133.7	 (2C),	 132.8	 (2C),	 127.0	 (2C),	 52.7	
(2C),	 35.5	 (2C).	MS	 (ESI+,	m/z):	 367	 [(M+H)+],	 389	 [(M+Na)+].	
Anal.	calcd.	for	C16H14O6S2:	C,	52.45;	H,	3.86.	Found:	C,	52.71;	H,	
4.23.	
	
2.2.1.2.	6,7‐Bis(1‐methoxycarbonylmethylthio)‐5,8‐
quinolinequinone	(15)	
	
Under	 argon,	 to	 a	 solution	of	methyl	 thioglycolate	 (98	µL,	
0.97	mmol)	 in	 THF	 (1	mL)	was	 added	 triethylamine	 (135	 µL,	
0.97	mmol)	 and	 after	 15	min	 6,7‐dichloroquinoline‐5,8‐dione	
(100	mg,	 0.44	mmol).	 After	 1	 h	 stirring,	 diethyl	 ether	 (5	mL)	
was	 added,	 which	 was	 followed	 by	 filtration.	 The	 residue	
obtained	 after	 evaporation	 of	 the	 volatiles	 was	 purified	 by	
column	 chromatography	 on	 silica	 gel	 (ethyl	 acetate)	 to	 afford	
15	as	a	red	oil.	Yield:	51%.	1H	NMR	(300	MHz,	CDCl3,	,	ppm):	
8.94	(dd,	1H,	J	=	4.5,	1.5	Hz,	Ar‐H),	8.34	(dd,	1H,	J	=	7.8,	1.5	Hz,	
Ar‐H),	7.62	(dd,	1H,	J	=	7.8,	4.5	Hz,	Ar‐H),	4.08	(s,	2H,	CH2),	4.00	
(s,	 2H,	CH2),	 3.68	 (s,	 3H,	 CH3),	 3.67	 (s,	 3H,	CH3).	 13C	NMR	 (75	
MHz,	 CDCl3,	 ,	 ppm):	 177.9	 (C=O),	 177.2	 (C=O),	 169.0	 (C=O),	
168.9	 (C=O),	 154.3	 (C),	 148.2	 (C),	 147.8	 (C),	 144.4	 (C),	 134.8	
(C),	 129.7	 (C),	127.4	 (C),	 52.7	 (C),	 52.6	 (C),	 35.3	 (C),	 35.2	 (C).	
MS	 (ESI+,	 m/z):	 368	 [(M+H)+],	 390	 [(M+Na)+].	 HRMS	 (ESI+)	
calcd.	for	C15H14NO6S2	[(M+H)+]:	368.02571.	Found:	368.02591.	
	
2.2.1.3.	6,7‐Bis(1‐methoxycarbonylmethylthio)‐5,8‐
phthalazinequinone	(16)	
	
A	solution	of	methyl	 thioglycolate	 (26	µL,	0.28	mmol)	and	
triethylamine	(40	µL,	0.28	mmol)	 in	THF	(0.7	mL)	was	stirred	
at	 room	 temperature	 during	 15	 min	 before	 addition	 of	 6,7‐
dichloro‐5,8‐phtalazinequinone	 (30	mg,	0.13	mmol).	After	2	h	
stirring,	 CH2Cl2	 and	water	were	 added	 and	 the	 aqueous	 layer	
was	 extracted	 (x3)	with	 CH2Cl2.	 The	 combined	 organic	 layers	
were	 washed	 with	 brine,	 dried	 over	 Na2SO4	 and	 evaporated	
under	 reduced	 pressure	 to	 afford	 6,7‐bis(methoxycarbonyl	
methylthio)‐5,8‐dihydroxyphthalazine	 (37	mg)	 as	 a	 brown	 oil	
(1H	NMR	(400	MHz,	CDCl3,	,	ppm):	9.82	(s,	2H,	Ar‐H),	3.67	(s,	
4H,	2CH2),	3.65	(s,	6H,	2CH3).	 IR	(film,	,	 cm‐1):	3383,	2953,	
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2924,	 1737,	 1435,	 1291,	 1197,	 1162,	 1127,	 1009.	 MS	 (ESI+,	
m/z):	371	 [(M+H)+])	which	was	oxidized	without	purification.	
Thus	11	mg	(0.030	mmol)	of	it	was	stirred	in	acetonitrile:water	
(1:1)	 (200	µL)	 to	which	was	added	dropwise	 a	 solution	of	 41	
mg	 of	 cerium	 ammonium	 nitrate	 (0.075	 mmol)	 in	
acetonitrile:water	 (20:1)	 (320	 µL).	 The	 mixture	 was	 then	
stirred	 at	 room	 temperature	 for	 30	min,	 before	 being	 diluted	
with	 an	 ice‐water	 slurry	 (5	 mL)	 and	 CH2Cl2	 (5	 mL).	 After	
separation	of	the	layers,	the	aqueous	phase	was	extracted	with	
CH2Cl2	(3x5	mL),	the	organic	layers	were	combined	and	washed	
with	 brine	 (5	 mL),	 dried	 over	 Na2SO4	 and	 evaporated	 under	
reduced	pressure.	Preparative	TLC	(Et2O)	gave	16	as	a	red	oil.	
Yield:	 10%.	 FT‐IR	 (film,	 cm‐1):	 3054,	 2986,	 2955,	 2925,	 1738	
(C=O),	 1666	 (C=O),	 1461,	 1438,	 1265,	 1158,	 896.	 1H	 NMR	
(400	 MHz,	 CDCl3,	 ,	 ppm):	 9.75	 (s,	 2H,	 Ar‐H),	 4.08	 (s,	 4H,	
2CH2),	3.72	(s,	6H,	2CH3).	13C	NMR	(100	MHz,	CDCl3,	,	ppm):	
177.5	(2C=O),	168.9	(2C=O),	146.3	(2C),	146.1	(2C),	125.4	(2C),	
52.9	(2C),	35.1	(2C).	MS	(ESI+,	m/z):	369	[(M+H)+].	HRMS	(ESI+)	
calcd.	for	C14H13N2O6S2	(M+H)+:	369.02095,	found:	369.02098.		
	
2.2.1.4.	2‐Methyl‐5,6‐bis(1‐methoxycarbonylmethylthio)‐4,7‐
benzoxazolequinone	(17)	
	
To	a	solution	of	21	(80	mg,	0.34	mmol)	in	ethanol	(1.7	mL)	
was	 added	 pyridine	 (80	 µL,	 0.99	 mmol)	 and	 the	 reaction	
mixture	was	cooled	to	0	°C	before	methyl	thioglycolate	(70	µL,	
0.76	mmol)	was	added.	Then,	the	reaction	mixture	was	stirred	
at	room	temperature	for	18	h	before	being	diluted	with	CH2Cl2	
(5	mL)	and	water	(5	mL)	and	the	aqueous	layer	was	extracted	
with	 CH2Cl2	 (3x5	 mL).	 The	 organic	 layers	 were	 combined,	
washed	with	 brine,	 dried	 over	 Na2SO4	 and	 evaporated	 under	
reduced	pressure	to	afford	a	burgundy‐red	oil	(25	mg)	which	is	
a	mixture	 of	17	 and	 5,6‐bis(methoxycarbonylmethylthio)‐4,7‐
dihydroxy‐2‐methyl‐benzo[d]oxazole	 (1H	 NMR	 (400	 MHz,	
CDCl3,	,	ppm):	8.62	(br	s,	2H,	OH),	4.05	(s,	4H,	2CH2),	3.73	(s,	
6H,	 2CH3),	 2.66	 (s,	 3H,	 CH3)).	 This	mixture	was	 diluted	with	
CHCl3:EtOH	 (1:1)	 (220	 µL)	 and	 cooled	 to	 0	 °C	 before	 the	
addition	 of	 a	 solution	 of	 FeCl3.6H2O	 (122	 mg,	 0.45	 mmol)	 in	
water	(110	µL).	After	stirring	for	30	min	at	room	temperature,	
CH2Cl2	(5	mL)	and	water	(5	mL)	were	added.	The	aqueous	layer	
was	extracted	with	CH2Cl2	(3	x	5	mL)	and	the	combined	organic	
layers	were	washed	with	brine	(5	mL),	dried	over	Na2SO4	and	
the	volatiles	were	removed	under	reduced	pressure.	The	dark	
purple	 oil	 thus	 obtained	 was	 purified	 by	 column	
chromatography	 on	 silica	 gel	 (Et2O:pentane,	 1:1)	 to	 afford	17	
as	 a	 dark	 red	 oil.	 Yield:	 79	%.	 FT‐IR	 (KBr,	 cm‐1):	 3054,	 2987,	
1739	 (C=O),	 1678	 (C=O),	 1421,	 1265,	 896.	 1H	 NMR	 (400	
MHz,	CDCl3,	,	ppm):	4.05	(s,	2H,	CH2),	3.99	(s,	2H,	CH2),	3.73	(s,	
3H,	CH3),	3.72	(s,	3H,	CH3),	2.55	(s,	3H,	CH3).	13C	NMR	(100	MHz,	
CDCl3,	 ,	 ppm):	 175.3	 (C=O),	 169.0	 (C=O),	 168.9	 (C=O),	 168.5	
(C=O),	163.8	(C),	158.0	(C),	147.6	(C),	141.9	(C),	119.6	(C),	52.8	
(C),	 52.8	 (C),	 35.8	 (C),	 35.2	 (C),	 10.6	 (C).	MS	 (ESI+,	m/z):	 372	
[(M+H)+],	 394	 [(M+Na)+].	 HRMS	 (ESI+)	 calcd.	 for	 C14H14NO7S2	
(M+H)+:	372.02062.	Found:	372.02112.	
	
2.2.1.5.	5,6‐Dichloro‐2‐methyl‐4,7‐benzo[d]oxazolequinone	
(21)	
	
Sodium	chlorate	(1.06	g,	10.0	mmol)	was	added	in	portions	
over	 a	 period	 of	 30	min	 to	 a	 stirred	 solution	 of	 4‐hydroxy‐2‐
methylbenzoxazole	(200	mg,	1.34	mmol)	in	conc.	HCl	(8	mL)	at	
65	 °C.	 After	 3	 h	 stirring	 at	 this	 temperature,	 the	 reaction	
mixture	was	cooled	 to	 room	temperature	before	dilution	with	
water	(20	mL)	and	CH2Cl2	(20	mL).	The	layers	were	separated	
and	 the	 aqueous	phase	was	 extracted	with	CH2Cl2	 (3x10	mL).	
The	organic	layers	were	combined,	washed	with	brine	(10	mL),	
dried	over	Na2SO4	 and	evaporated	under	 reduced	pressure	 to	
afford	 an	 orange	 solid	 which	 was	 recrystallized	 from	
CH2Cl2/MeOH	 to	 give	 21	 as	 a	 yellow	 solid.	 Yield:	 25%.	 M.p.:	
197‐199	 °C.	 FT‐IR	 (KBr,	 cm‐1):	 3387,	 1688	 (C=O),	 1616	
(C=O),	1543,	1174,	812.	 1H	NMR	 (400	MHz,	CD3OD,	,	 ppm):	
2.58	(s,	3H,	CH3).	 13C	NMR	(100	MHz,	Acetone,	,	ppm):	173.4	
(C=O),	167.7	 (C=O),	165.6	 (C),	 159.9	 (C),	 144.2	 (C),	 142.4	 (C),	
120.6	 (C),	 11.4	 (C).	MS	 (ESI+,	m/z):	 233	 [(M+H)+].	Anal.	 calcd.	
for	 C8H3Cl2NO3:	 C,	 41.42;	H,	 1.31;	N,	 6.04.	 Found:	 C,	 41.29;	H,	
1.54;	N,	5.67%.	
	
2.2.1.6.	5,6‐Bis(1‐methoxycarbonylmethylthio)‐4,7‐benzo	
[b]thiophenequinone	(22)	
	
A	solution	of	benzo[b]thiophene‐4,7‐quinone	 (49	mg,	0.30	
mmol)	in	95%	EtOH	(6	mL)	was	added	to	a	solution	of	methyl	
thioglycolate	 (56	 µL,	 0.62	 mmol)	 in	 95%	 EtOH	 (6	 mL)	 The	
resulting	solution	was	refluxed	for	1	h	and	after	cooling,	it	was	
diluted	 with	 water	 (10	 mL)	 and	 CH2Cl2	 (10	 mL).	 The	 layers	
were	 separated	 and	 the	 aqueous	 phase	 was	 extracted	 with	
CH2Cl2	 (3x10	mL).	The	combined	organic	 layers	were	washed	
with	 brine	 (10	mL),	 dried	 over	Na2SO4	 and	 evaporated	under	
reduced	pressure	to	afford	light	yellow	oil	(70	mg).	This	oil	was	
diluted	 with	 acetonitrile:water	 (1:1)	 (1.4	 mL)	 before	 the	
dropwise	 addition	 of	 a	 solution	 of	 cerium	 ammonium	 nitrate	
(321	mg,	0.58	mmol)	in	20:1	of	acetonitrile:water	(2.7	mL).	The	
mixture	 was	 stirred	 at	 room	 temperature	 for	 30	 min	 before	
dilution	with	an	ice/water	slurry	(5	mL)	and	CH2Cl2	(5	mL).	The	
layers	 were	 separated	 and	 the	 aqueous	 layer	 was	 extracted	
with	 CH2Cl2	 (3x5	 mL).	 The	 combined	 organic	 layers	 were	
washed	with	brine	 (5	mL),	dried	over	Na2SO4	and	evaporated	
under	 reduced	 pressure	 to	 afford	 a	 red	 solid	 (60	 mg).	 This	
material	was	 taken	up	 in	95%	EtOH	 (4.5	mL)	 and	 added	 to	 a	
solution	 of	 methyl	 thioglycolate	 (42	 µL,	 0.47	 mmol)	 in	 95%	
EtOH	(4.5	mL).	The	resulting	solution	was	then	refluxed	for	140	
min	 and	 after	 cooling,	 was	 diluted	 with	 water	 (10	 mL)	 and	
CH2Cl2	 (10	 mL).	 The	 layers	 were	 separated	 and	 the	 aqueous	
phase	was	extracted	with	CH2Cl2	(3x10	mL).	The	organic	layers	
were	combined,	washed	with	brine	(10	mL),	dried	over	Na2SO4	
and	evaporated	under	 reduced	pressure	 to	afford	a	brown	oil	
(91	mg).	Once	this	oil	was	taken	up	in	acetonitrile:water	(1:1)	
(1.4	mL)	 a	 solution	 of	 ceric	 ammonium	nitrate	 (333	mg,	 0.61	
mmol)	 in	 acetonitrile:water	 (20:1)	 (2.7	 mL)	 was	 added	
dropwise.	After	stirring	for	30	minutes,	an	 ice/water	slurry	(5	
mL)	 and	 CH2Cl2	 (5	 mL)	 were	 added.	 The	 aqueous	 layer	 was	
then	extracted	with	CH2Cl2	(3x5	mL)	and	the	combined	organic	
layers	were	washed	with	brine	(5	mL),	dried	over	Na2SO4	and	
evaporated	under	reduced	pressure	to	afford	a	dark	purple	oil	
that	 was	 purified	 by	 column	 chromatography	 (CH2Cl2)	 over	
silica	 gel	 to	 give	22	 as	 a	 purple	 oil.	 Yield:	 40	%.	 FT‐IR	 (film,					
cm‐1):	 3054,	 2987,	 2955,	 1736	 (C=O),	 1663	 (C=O),	 1437,	
1265,	1147.	1H	NMR	(300	MHz,	CDCl3,	,	ppm):	7.62	(d,	1H,	J	=	
4.8	Hz,	Ar‐H),	7.48	 (d,	1H,	 J	 =	4.8	Hz,	Ar‐H),	4.00	 (s,	2H,	CH2),	
3.99	 (s,	 2H,	 CH2),	 3.71	 (br	 s,	 6H,	 2CH3).	 13C	 NMR	 (100	MHz,	
CDCl3,	 ,	 ppm):	 174.9	 (C=O),	 173.5	 (C=O),	 169.2	 (C=O),	 169.1	
(C=O),	 145.1	 (C),	 144.8	 (C),	 143.3	 (C),	 141.6	 (C),	 133.7	 (C),	
126.7	(C),	52.7	(C),	52.6	(C),	35.7	(C),	35.6	(C).	MS	(ESI+,	m/z):	
372	 [(M+H)+],	 394	 [(M+Na)+].	 HRMS	 (ESI+)	 calcd.	 for	
C14H12O6S3Na	(M+Na)+:	394.96882.	Found:	394.96943.	
	
2.2.1.7.	2‐Methyl‐5,6‐bis(1‐methoxycarbonylmethylthio)‐4,7‐
benzo[d]thiazolequinone	(23)	
	
Compound	23	was	obtained	as	a	purple	oil	from	2‐methyl‐
4,7‐benzo[d]thiazolequinone,	 using	 the	 procedure	 described	
for	the	preparation	of	22.	Yield:	46	%.	FT‐IR	(film,	cm‐1):	3053,	
2986,	 1739	 (C=O),	 1671	 (C=O),	 1422,	 1265.	 1H	 NMR	 (400	
MHz,	CDCl3,	,	ppm):	4.04	(s,	2H,	CH2),	3.97	(s,	2H,	CH2),	3.71	(s,	
3H,	CH3),	3.70	(s,	3H,	CH3),	2.81	(s,	3H,	CH3).	13C	NMR	(100	MHz,	
CDCl3,	 ,	 ppm):	 173.7	 (C=O),	 173.4	 (C=O),	 173.3	 (C=O),	 169.1	
(C),	 169.0	 (C),	 153.2	 (C),	 145.3	 (C),	 143.5	 (C),	 140.0	 (C),	 52.8	
(C),	 52.7	 (C),	 35.7	 (C),	 35.6	 (C),	 20.0	 (C).	MS	 (ESI+,	m/z):	 410	
[(M+Na)+].	 HRMS	 (ESI+)	 calcd.	 for	 C14H14NO6S3	 (M+H)+:	
387.99778,	found:	387.99872.		
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2.2.1.8.	6,7‐Bis(1‐methoxycarbonylmethylthio)‐5,8‐
quinazolinequinone	(24)	
	
Compound	 24	 was	 obtained	 from	 5,8‐quinazolequinone	
using	the	procedure	described	for	the	preparation	of	22.	Yield:	
31	 %.	 FT‐IR	 (film,	 cm‐1):	 2996,	 2954,	 1737	 (C=O),	 1666	
(C=O),	1566	(Aromatic,	C=C),	1435,	1280.	1H	NMR	(400	MHz,	
CDCl3,	,	ppm):	9.58	(s,	1H,	Ar‐H),	9.42	(s,	1H,	Ar‐H),	4.09	(s,	2H,	
CH2),	4.07	(s,	2H,	CH2),	3.70	 (s,	3H,	CH3)	3,68	(s,	3H,	CH3).	 13C	
NMR	(100	MHz,	CDCl3,	,	ppm):	176.8	(C=O),	176.4	(C=O),	168.9	
(C=O),	168.8	 (C=O),	162.5	 (C),	 157.2	 (C),	 153.5	 (C),	 147.3	 (C),	
145.5	 (C),	 125.3	 (C),	 52.9	 (C),	 52.8	 (C),	 35.2	 (C),	 35.1	 (C).	MS	
(ESI+,	m/z):	 369	 [(M+H)+],	 391	 [(M+Na)+].	 HRMS	 (ESI+)	 calcd.	
for	C14H13N2O6S2	(M+H)+:	369.02095.	Found:	369.02101.	
	
2.2.1.9.	6,7‐Bis(1‐methoxycarbonylmethylthio)‐5,8‐
quinoxalinequinone	(25)	
	
Methyl	 thioglycolate	 (25	 µL,	 0.275	 mmol)	 and	
triethylamine	(38	µL,	0.275	mmol)	were	mixed	in	THF	(620	µL)	
at	 room	 temperature	 and	 stirred	 for	 15	 min	 before	 5,8‐
quinoxalinequinone	 (20	 mg,	 0.125	 mmol)	 was	 added.	 After	
stirring	 for	 12h,	 the	volatiles	were	 evaporated	under	 reduced	
pressure	 and	 the	 residue	 was	 dissolved	 in	 water	 and	 then	
extracted	with	CH2Cl2	(3x10	mL).	The	combined	organic	layers	
were	 washed	 with	 brine	 (15	 mL),	 dried	 over	 Na2SO4	 and	
evaporated	 under	 reduced	 pressure	 to	 afford	 a	 yellow	 solid	
which	 was	 purified	 by	 column	 chromatography	 on	 silica	 gel	
(Et2O:MeOH,	94:6)	 and	crystallized	 from	hot	ethanol	 to	afford	
5,8‐dihydroxy‐6,7‐bis(1‐methoxycarbonylmethylthio)quino‐
xaline	 (17	mg,	 37	%)	 as	 a	 yellow	 solid.	 M.p.:	 129‐130	 °C.	 1H	
NMR	(400	MHz,	CDCl3,	,	ppm):	8.83	(s,	2H,	Ar‐H),	8.01	(s,	2H,	
OH),	3.86	(s,	4H,	2CH2),	3.68	(s,	6H,	2CH3).	13C	NMR	(75	MHz,	
CDCl3,	,	 ppm):	 170.4	 (2C=O),	 147.3	 (C),	 144.3	 (C),	 133.6	 (C),	
119.3	(C),	52.7	(C),	36.7	(C).	IR	(KBr,	,	cm‐1):	1720,	1439,	1400,	
1278,	1154,	1121,	1100.	HRMS	(ESI+)	calcd.	for	C14H14N2O6S2Na	
(M+Na)+:	393.01855,	Found:	393.01857.	This	material	(17	mg,	
0.046	mmol)	was	taken‐up	in	acetonitrile:water	(1:1)	(500	µL),	
to	 which	 was	 added	 dropwise	 under	 stirring	 a	 solution	 of	
cerium	 ammonium	 nitrate	 (55	 mg,	 0.101	 mmol)	 in	
acetonitrile:water	 (20:1)	 (950	 µL).	 The	 mixture	 was	 then	
stirred	 at	 room	 temperature	 for	 30	min	 before	 being	 diluted	
with	a	ice/water	slurry	(5	mL)	and	CH2Cl2	(5	mL).	The	aqueous	
phase	was	 extracted	with	 CH2Cl2	 (4x5	mL)	 and	 the	 combined	
organic	layers	were	washed	with	brine	(5	mL),	and	dried	over	
Na2SO4.	 Evaporation	 of	 the	 volatiles	 under	 reduced	 pressure	
afforded	 a	 dark	 purple	 oil	 which	 was	 purified	 by	 column	
chromatography	on	silica	gel	(CH2Cl2	then	CH2Cl2:MeOH,	95:5)	
to	give	25	as	an	orange	oil.	Yield:	24%.	FT‐IR	(film,	cm‐1):	3003,	
2954,	2924,	2851,	1731	(C=O),	1667	(C=O),	1530	(Aromatic	
C=C),	1485,	1435,	1286,	1191,	1004.	1H	NMR	(300	MHz,	CDCl3,	
,	 ppm):	 8.69	 (s,	 2H,	 Ar‐H),	 4.12	 (s,	 4H,	 2CH2),	 3.70	 (s,	 6H,	
2CH3).	13C	NMR	(75	MHz,	CDCl3,	,	ppm):	176.7	(2C=O),	169.0	
(2C=O),	 148.6	 (C),	 146.6	 (C),	 144.6	 (C),	 52.8	 (C),	 35.2	 (C).	MS	
(ESI+,	 m/z):	 369	 [(M+H)+],	 391	 [(M+Na)+].	 Anal.	 calcd.	 for	
C14H12N2O6S2:	C,	45.65;	H,	3.28;	N,	7.60.	Found:	C,	45.89;	H,	3.22;	
N,	7.23%.	
	
2.2.1.10.	5,6‐Bis(1‐methoxycarbonylmethylthio)‐4,7‐
indolequinone	(26)	
	
Methyl	thioglycolate	(94	µL,	1.05	mmol)	and	triethylamine	
(150	 µL,	 1.0	 mmol)	 were	 added	 to	 THF	 (4.8	 mL)	 and	 the	
mixture	was	stirred	at	room	temperature	for	15	min	before	the	
addition	 of	 4,7‐indolequinone	 (70	 mg,	 0.476	 mmol).	 The	
reaction	mixture	 was	 stirred	 for	 16	 h,	 then	was	 diluted	with	
water	 (5	 mL)	 and	 CH2Cl2	 (5	 mL).	 The	 aqueous	 layer	 was	
extracted	 with	 CH2Cl2	 (3x10	 mL)	 and	 the	 combined	 organic	
layers	were	washed	with	brine	(15	mL),	dried	over	Na2SO4	and	
evaporated	 under	 reduced	 pressure.	 Purification	 of	 the	 crude	
product	was	achieved	by	column	chromatography	on	silica	gel	
(CH2Cl2:AcOEt,	94:6)	to	give	26	as	a	purple	oil.	Yield:	36%.	FT‐
IR	 (KBr,	 cm‐1):	 3300	 (N‐H),	 2953,	 2926,	 1737	 (C=O),	 1649	
(C=O),	 1435,	 1381,	 1292,	 1194,	 1157,	 1124,	 1008.	 1H	 NMR	
(300	MHz,	 CDCl3,	 ,	 ppm):	 10.28	 (br	 s,	 1H,	 NH),	 7.01	 (d,	 1H,									
J=2.7	Hz,	Ar‐H),	6.55	(d,	1H,	J	=	2.7	Hz,	Ar‐H),	4.01	(s,	2H,	CH2),	
3.94	(s,	2H,	CH2),	3.73	(s,	3H,	CH3),	3.72	(s,	3H,	CH3).	 13C	NMR	
(75	 MHz,	 CDCl3,	 ,	 ppm):	 176.6	 (C=O),	 171.2	 (C=O),	 169.8	
(C=O),	169.6	 (C=O),	146.8	 (C),	 141.5	 (C),	 130.8	 (C),	 126.2	 (C),	
126.0	 (C),	 109.4	 (C),	 52.7	 (C),	 52.6	 (C),	 36.1	 (C),	 35.8	 (C).	MS	
(ESI+,	m/z):	 356	 [(M+H)+],	 378	 [(M+Na)+].	 HRMS	 (ESI+)	 calcd.	
for	 C14H14NO6S2	 (M+H)+:	 356.02571.	 Found:	 356.02617.	 Anal.	
Calcd.	 for	 C14H13NO6S2:	 C,	 47.31;	 H,	 3.69;	 N,	 3.94.	 Found:	 C,	
47.89;	H,	3.85;	N,	3.76%.	
	
2.2.2.	In	vitro	enzymatic	assay	
	
The	activity	of	the	MBP‐CDC25B	[22]	recombinant	enzyme	
was	monitored	 using	 fluorescein	 diphosphate.	 The	 assay	was	
performed	in	96‐well	plates	in	a	 final	volume	of	200	µL.	MBP‐
CDC25B3	was	 diluted	 in	 assay	 buffer	 [30	mM	Tris‐HCl	 (pH	 =	
8.2),	75	mM	NaCl,	0.67	mM	EDTA,	0.033%	BSA,	1	mM	DTT]	so	
that	 the	 final	concentration	was	90	ng/well.	The	 reaction	was	
initiated	 by	 addition	 of	 25	 µM	 of	 fluorescein	 diphosphate	
followed	by	immediate	measurement	of	fluorescein	phosphate	
emission	 with	 a	 Fluoroskan	 Ascent	 (Lab	 Systems;	 excitation	
filter:	 485	 nm,	 emission	 filter:	 530	 nm).	 For	 each	 compound,	
the	drug	concentration	required	 for	50%	inhibition	(IC50)	was	
determined	 from	 a	 sigmoidal	 dose‐response	 curve	 using	
GraphPad	Prism	4	(GraphPad	Software,	San	Diego,	CA).	Results	
are	 expressed	 as	 the	 mean	 of	 at	 least	 two	 independent	
experiments	 with	 three	 determinations	 per	 tested	
concentration	and	per	experiment.	
	
2.2.3.	Cell	proliferation	assay	
	
The	inhibition	of	cell	proliferation	was	determined	using	a	
colorimetric	 assay	 based	 on	 the	 cleavage	 of	 the	 WST‐1	
tetrazolium	 salt	 by	 mitochondrial	 dehydrogenases	 in	 viable	
cells,	 leading	 to	 formazan	 formation.	 At	 day	 0,	 HeLa	 and	
MiaPaCa‐2	 cells	 were	 plated	 at	 5500	 and	 5000	 cells/well,	
respectively	 in	 96‐well	 culture	 plates	 with	 95	 µL	 of	
medium/well.	At	day	1,	cells	were	treated	for	48	h	with	5	µL	of	
increasing	concentrations	of	drug	(dissolved	in	DMSO,	to	a	final	
concentration	 <	 0.05%).	 At	 day	 3,	 after	 addition	 of	 10	 µL	 of	
WST‐1	 per	 well,	 cells	 were	 incubated	 2	 hours	 at	 37	 °C	 in	 a	
humidified	 atmosphere	 of	 5%	 CO2.	 Absorbance	 was	 then	
measured	 at	 490	 nm	 with	 a	 Bio‐Rad	 microplate	 reader.	 The	
results	 are	 expressed	 as	 the	 mean	 of	 three	 independent	
experiments	 with	 three	 determinations	 per	 tested	
concentration	 and	 per	 experiment.	 The	 IC50	 value	 were	
determined	 from	 a	 sigmoidal	 dose‐response	 using	 GraphPad	
Prism	(GraphPad	Software,	San	Diego,	CA).		
	
3.	Results	and	discussion		
	
3.1.	Chemistry	
	
Parent	 compound	 bis(methoxycarbonylmethylthio)	
naphthaquinone,	 14,	 was	 prepared	 from	 6,7‐dichloro‐
naphthoquinone,	 13,	 by	 nucleophilic	 attack	 of	 methyl	
mercaptoacetate	[23].		
Compounds	 15	 and	16	 were	 obtained	 from	 6,7‐dichloro‐
5,8‐quinolinequinone,	 18,	 [24]	 and	 6,7‐dichloro‐5,8‐
phthalazinequinone,	 19,	 [24],	 respectively,	 using	 ‘reverse	
addition’	conditions	(i.e.	addition	of	the	dichloroheteroquinone	
to	 a	 solution	 of	 sodium	 methoxy	 carbonylmethyl‐thiolate).	
Derivative	17	was	synthesized	from	5,6‐dichloro‐2‐methyl‐4,7‐
benzoxazolequinone,	21,	prepared	by	oxidative	halogenation	of	
7‐hydroxy‐2‐methylbenzoxazole,	20,	[25].		
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Figure	2.	Addition	of	a	thiol	onto	heteroquinones	(regioisomers	are	not	highlighted).
	
	 	
Since	 bis(methoxycarbonylmethyl‐thio)hydroquinones	 are	
the	primary	products	obtained	from	19	or	21,	an	oxidation	step	
was	 required	which	was	 carried	 out	 conventionally	 (FeCl3	 or	
CAN)	(Scheme	1).	
When	 thiols	 react	 with	 unsubstituted	 quinones,	 three	
intermediates	are	met	en	route	 to	get	a	disubstituted	quinone	
(Scheme	 2).	 These	 can	 be	 observed	 spectroscopically	 but	 do	
not	 need	 to	 be	 isolated	 as	 a	 sequential	 addition/oxidation/	
addition/oxidation	 process	 can	 be	 carried	 out	 up	 to	 the	 final	
product,	 as	 it	 has	 been	 previously	 exemplified	 for	 the	
preparation	of	bis(thio)	derivatives	of	quinocarcin	[26].	
Accordingly,	 reacting	 benzo[b]thiophene‐4,7‐quinone	
[27,28],	 2‐methyl‐4,7‐benzo[d]thiazolequinone	 [29‐32]	 and	
5,8‐quinazolinequinone	 [33,34]	 with	 methyl	 mercaptoacetate,	
followed	 by	 oxidation	 (CAN)	 in	 a	 stepwise	 and	 duplicated	
manner	 (see	 experimental	 section),	 afforded	 bis‐substituted	
heteroquinones,	 22‐24,	 (Figure	 2).	 Concerning	 the	 5,8‐
quinoxalinequinone	 scaffold	 [24,35,36],	 it	 yielded	 a	 bis‐
(thio)hydroquinone	 in	 a	 single	 step	 which	 was	 followed	 by	
oxidation	 to	 get	25.	Moreover,	 in	 the	 case	 of	 indole‐4,7‐dione	
[37,38],	 the	 bis‐substituted	 quinone,	 26,	 could	 be	 obtained	
directly,	 i.e.	 without	 the	 need	 for	 an	 external	 oxidizing	 agent,	
which	 presumably	 arises	 from	 relative	 redox	 properties	 of	
intermediate	species	within	the	reaction	system.		
Although	 bis(methoxycarbonylmethylthio)‐heteroquino‐
nes,	14‐17	and	22‐26	have	been	isolated	in	fair‐to‐low	(but	un‐
optimized)	yields	 (Figure	3),	 they	have	been	obtained	 in	pure	
state,	 which	 has	 allowed	 their	 evaluation	 on	 CDC25	
phosphatase	enzymatic	activity.	
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Table	1.	Inhibitory	activities	of	heteroquinones	14‐17	and	22‐26	toward	CDC25.	
Compound	 Structure	 IC50±SEM	(µM) Compound Structure IC50±SEM	(µM)
Menadione	
	
2.20±0.60	 22	
	
1.30±0.03	
14	
	
1.17±0.04	 23	
	
3.81±0.06	
15	
	
1.63±0.21	 24	
	
1.83±0.28	
16	
	
3.38±0.17	 25	
	
5.40±1.81	
17	
	
5.70±0.47	 26	
	
4.49±1.45	
aThe	IC50	values	were	calculated	from	three	independent	experiments.	
	
	
 
	
Figure	3.	Structures	of	quinones,	22‐26.	
	
	
3.2.	Enzymatic	activity	studies	
	
The	nine	newly	synthesized	heteroquinones,	14‐17	and	22‐
26	 were	 examined	 for	 their	 inhibitory	 activity	 against	 the	
recombinant	 protein	 MBP‐CDC25B	 using	 fluorescein‐3,6‐
diphosphate	 (FDP)	 as	 the	 artificial	 substrate.	 The	 fluorescent	
emission	 resulting	 from	 dephosphorylation	 was	 monitored	
during	 30	 min	 at	 30	 °C	 in	 the	 presence	 of	 increasing	
concentrations	 of	 inhibitors	 [21].	 Menadione	 was	 used	 as	 a	
reference.	Results	are	reported	in	Table	1.	
All	 tested	 quinones	 show	 comparable	 inhibitory	 activities	
with	IC50	values	ranging	from	1.17	to	5.70	µM,	naphthoquinone	
being	 the	 most	 potent	 pharmacophore	 for	 this	 set	 of	
heteroquinones.	With	regard	to	the	six‐membered	heterocyclic	
derivatives,	 14‐16,	 and	 24‐25,	 increasing	 the	 number	 of	
nitrogen	 atoms	 on	 the	 heterocycle	 led	 to	 a	 slight	 decrease	 of	
activity,	 quinoxalinequinone,	 25,	 being	 the	 less	 potent	
inhibitor.		
The	parent	compound	14	with	two	methyl	ester	groups	 is	
10‐fold	 less	 potent	 than	 the	 bis(2‐hydroxyethylthio)	 analogue	
NSC95397	 [12]	 for	 which	 an	 IC50	 of	 125	 nM	 was	 reported	
though	 we	 previously	 measured	 for	 this	 compound	 an	 IC50	
value	of	3.8	µM	under	our	conditions	[21].	On	the	other	hand,	
14	 displayed	 similar	 activity	 when	 compared	 with	 the	 bis‐
carboxylic	acid	3	and	the	corresponding	benzyl	di‐ester	4	[21].		
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Table	2.	In	vitro	growth	inhibition	of	HeLa	and	MiaPaCa‐2	cell	lines.	
Compound	 HeLa	%	of	growth	inhibition	 MiaPaCa‐2	%	of	growth	inhibition 
100	µM	 10	µM 100	µM 10	µM 
Menadione	 IC50	=	37.5±3.5	µM	 IC50	=	33	µM	
15	 79±0.9	 13±0.9 77±2.1	 24±15.4	
16	 60±2.1	 21.0±1.5	 	 	 74±0.7	 10±3.7	
17	 62±3.1	 6.0±4.1 75±1.2	 0	
22	 IC50	=	26.9±6.3	µM	 IC50	=	29.0±		µM	
23	 IC50	=	34.5±4.9	µM	 78±1.7	 27	
24	 47.0±5.5	 22.0±3.0 71±0.2	 4±3.6	
25	 0	 0	 24±4.6	 6±4.8	
26	 82.0±0.9	 8.0±6.2	 	 	 75±2.0	 5±5.0	
	
	
In	contrast,	 the	bis‐ester	quinolinequinone	15	 (IC50	=	1.63	
µM)	 is	 more	 than	 5‐fold	 more	 potent	 than	 its	 bis‐carboxylic	
acid	counterpart	(IC50	=	11.2	µM	for	5)	[17].	
Within	 the	 five‐membered	 heterocycle	 sub‐set,	 benzoxa‐
zolequinone,	 17,	 and	 benzothiazolequinone,	 23,	 bearing	 a	
methyl	 group	 on	 the	 heterocyclic	 moiety	 did	 not	 lead	 to	 the	
expected	 increase	 of	 activity	when	 compared	with	11	 and	12	
[19].	 Extending	 the	 scope	 of	 the	 study	 to	 scaffolds	 such	 as	
benzothiophenequinone,	22,	and	indolequinone,	26,	which	had	
not	 been	 previously	 considered	 for	 CDC25	 inhibition	 did	 not	
bring	any	improvement.	
Finally,	when	comparing	both	sub‐families,	results	indicate	
that	 the	 six‐membered	 heterocyclic	 derivatives	 are	 slightly	
more	 active	 than	 the	 five‐membered	 heterocyclic	 set,	
benzothiophenequinone,	22,	being	an	exception.	
	
3.3.	Antiproliferative	activity	
	
The	 cytotoxicity	 of	 8	 quinonoid‐based	 CDC25B	 inhibitors	
was	evaluated	on	the	human	cancer	cell	lines	HeLa	(cervix)	and	
MiaPaCa‐2	 (pancreatic	 adenocarcinoma)	 using	 a	 WST‐1	
colorimetric	 cleavage	 assay.	 The	 percentage	 of	 growth	
inhibition	 was	 determined	 at	 100	 µM	 and	 10	 µM	 for	 all	
compounds	 and	 the	 IC50	 values	 were	 measured	 for	 the	 most	
efficient	heterocyclic	quinones	only.	Menadione	was	also	tested	
and	 inhibited	HeLa	 and	MiaPaCa‐2	 cell	 lines	with	 comparable	
IC50	of	37.5	and	33	µM,	respectively	(Table	2).	
All	 compounds	showed	cytotoxic	 activity	 toward	both	 cell	
lines	 at	 100	 µM	with	 percentages	 of	 growth	 inhibition	 above	
60%	except	derivative,	25,	which	was	totally	inactive	on	HeLa	
cells	 and	displayed	a	percentage	of	24%	 inhibition	at	100	µM	
toward	the	pancreatic	cell	 line.	These	series	of	quinone	is	 less	
potent	 on	 HeLa	 cells	 than	 compounds	1	 and	2	 for	 which	we	
previously	reported	IC50	values	of	8.8	and	10.8	µM,	respectively	
[21].	 Benzothiophenequinone,	 22,	 which	 also	 showed	 one	 of	
the	 highest	 anti‐phosphatase	 activity	 was	 the	 most	 cytotoxic	
quinone	with	activities	comparable	to	that	of	menadione.	
	
4.	Conclusion	
	
Quinonoid‐based	compounds	are	currently	the	most	potent	
CDC25	 phosphatase	 inhibitors.	 In	 the	 present	 study,	 we	
examined	the	effect	on	CDC25B	activity	of	heterocycles	fused	to	
the	 1,4‐dione	 pharmacophore	 substituted	 with	 two	 thiol	
groups.	 For	 this	 limited	 series	 of	 bis‐substituted	
heteroquinones,	 important	 modifications	 of	 the	 heterocyclic	
ring	 are	 well	 tolerated	 since	 all	 derivatives	 show	 similar	
micromolar	 activities.	 Unfortunately,	 we	 were	 not	 able	 to	
increase	the	affinity	of	the	quinonic	compounds	by	modulating	
the	 heterocyclic	 part	 as	 expected.	 These	 results	 underline	 the	
role	of	 substitution	of	 the	quinone	 ring,	which	 is	 essential	 for	
potent	CDC25	 inhibition	 [12,19].	Thus,	 for	 this	set	of	quinonic	
derivatives,	 the	substitution	pattern	appears	to	be	responsible	
for	the	moderate	inhibitory	activity	level	and	probably	explains	
the	 absence	 of	 significant	 differences	 in	 activities	 between	
these	 heteroquinones.	 Therefore,	 it	 could	 be	 valuable	 to	
prepare	 and	 evaluate	 on	 CDC25	 phosphatase	 activity	
heteroquinones	 bearing	 two	N,N‐dimethylethylenediamino	 or	
2‐hydroxyethylthio	groups	on	the	quinone	ring.		
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